Accessibility Menu
Moberg Pharma Ab (publ) logo

Moberg Pharma Ab (publ)(OM) MOB

Market CapSEK 515.21MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-95%
5 Year-72%
1 Year+37%
1 Month+18%
SEK 11.14
+2.01%
+0.22Today
Moberg Pharma Ab (publ) last closing stock price
MetricPriceDate
Last closeSEK 11.142026-08-31
Moberg Pharma Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.08%SEK 10.122026-08-24
1 month+17.88%SEK 9.452026-07-31
3 month+10.96%SEK 10.042026-06-02
Year to date+8.47%SEK 10.272025-12-30
1 year+37.02%SEK 8.132025-08-29
3 year+56.9%SEK 7.102023-09-01
5 year-72.18%SEK 40.042021-09-01
Since inception-95.13%SEK 224.332011-05-26

Moberg Pharma Ab (publ) Financials at a Glance

Market Cap

SEK 515.21MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 16.76M

Net Income (TTM)

-SEK 21.62M

EPS (TTM)

-SEK 0.46

P/E Ratio

-23.73

Dividend

SEK 0.00

Beta (Volatility)

0.43 (Low)

Price

SEK 11.14

Volume

44,525

Open

SEK 10.90

Previous Close

SEK 10.92

Daily Range

SEK 10.50 - SEK 11.16

52-Week Range

SEK 7.53 - SEK 14.12

Estimated Earnings Date

Nov 12, 2026

MOB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Moberg Pharma Ab (publ)

Moberg Pharma AB (publ) is a pharmaceutical company focused on developing and marketing medical solutions globally, particularly in Europe and the United States. Established in 2006 and headquartered in Bromma, Sweden, the company is known for its innovative product MOB-015, a treatment for nail fungus that has successfully completed Phase III clinical trials.

Products and Services
  • MOB-015: A treatment for nail fungus
  • Medical solutions targeting various dermatological conditions
  • Global marketing and distribution of pharmaceutical products
Growth Outlook
  • Successful completion of Phase III trials for MOB-015 enhances market potential
  • Strong cash position with SEK 222 million available for future investments
  • Focus on expanding product portfolio to capture new market segments
Financial Highlights
  • Recent quarterly revenue of SEK 4.9 million, showing growth from previous quarters
  • Gross profit margin improved to 66.2% in Q1 2026
  • Current ratio of 13.12 indicates strong liquidity position
Moberg Pharma AB (publ) operates in the specialized drug manufacturing sector, with a focus on innovative treatments. The company has made significant strides in its product development, particularly with MOB-015, which positions it well in the competitive pharmaceutical landscape. The recent financial performance indicates a positive trend, with increasing revenue and a strong gross profit margin, reflecting effective cost management and operational efficiency. The robust liquidity position, highlighted by a current ratio of 13.12, provides the company with the flexibility to pursue growth opportunities and navigate market challenges. Overall, Moberg Pharma presents a compelling case for potential investors interested in the pharmaceutical sector.
AI Generated • Aug 11, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5

CEO

Anna Ljung

Website

www.mobergderma.se

Headquarters

Bromma, AB 167 51, SE

MOB Financials

Key Financial Metrics (TTM)

Gross Margin

62.31%

Operating Margin

-149.56%

Net Income Margin

-128.96%

Return on Equity

-3.24%

Return on Capital

-4.19%

Return on Assets

-3.17%

Earnings Yield

-4.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

SEK 515.21MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

47.18M

Volume

44.52K

Avg. Volume

76.76K

Financials (TTM)

Gross Profit

SEK 10.44M

Operating Income

-SEK 25.07M

EBITDA

-SEK 23.00M

Operating Cash Flow

-SEK 13.45M

Capital Expenditure

-SEK 15.93M

Free Cash Flow

-SEK 34.21M

Cash & ST Invst.

SEK 212.43M

Total Debt

SEK 1.72M

Moberg Pharma Ab (publ) Performance Analysis

Moberg Pharma Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 207,000N/A
20232023-12-31SEK 0N/A
20242024-12-31SEK 9,811,000N/A
20252025-12-31SEK 13,538,00038.0%
Moberg Pharma Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3011.4%
Q42025-12-31-48.4%
Q12026-03-31138.1%
Q22026-06-3017.1%
Moberg Pharma Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -1.38N/A
20232023-12-31SEK -1.33-3.7%
20242024-12-31SEK -6.74407.2%
20252025-12-31SEK -0.58-91.4%
Moberg Pharma Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3043.8%
Q42025-12-31-200.0%
Q12026-03-3190.0%
Q22026-06-30-159.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 5.77M

+60.3%

Gross Profit

SEK 3.77M

+122.0%

Gross Margin

65.35%

N/A

Market Cap

SEK 515.21MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

SEK 103.04M

N/A

Employees

5

N/A

Net Income

-SEK 3.28M

+55.6%

EBITDA

-SEK 6.85M

+17.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 212.43M

-16.6%

Total Debt

SEK 1.72M

-48.8%

Accounts Receivable

SEK 10.19M

+53.6%

Inventory

SEK 3.79M

-49.7%

Long Term Debt

SEK 0.00

-100.0%

Short Term Debt

SEK 1.72M

+5.1%

Return on Assets

-3.17%

N/A

Return on Invested Capital

-3.78%

N/A

Free Cash Flow

-SEK 3.25M

+76.4%

Operating Cash Flow

-SEK 3.25M

-60.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About MOB

What is the current price of Moberg Pharma Ab (publ)?

Moberg Pharma Ab (publ) is trading at SEK 11.14 per share.

What is the 52-week range for Moberg Pharma Ab (publ)?

Over the past 52 weeks, Moberg Pharma Ab (publ) has traded between SEK 7.53 and SEK 14.12.

How much debt does Moberg Pharma Ab (publ) have?

As of the most recent reporting period, Moberg Pharma Ab (publ) reported total debt of SEK 1.72M.

How much cash does Moberg Pharma Ab (publ) have on hand?

Moberg Pharma Ab (publ) reported SEK 212.43M in cash and cash equivalents in its most recent financial results.

What is Moberg Pharma Ab (publ)’s dividend yield?

Moberg Pharma Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services